The size of the Biomarkers Market in the Asia Pacific is predicted to reach USD 12.15 billion by 2025 from USD 5.74 billion in 2020, growing at a CAGR of 16.20% during the forecast period.
The high incidence of cancer drives research programs is majorly propelling the demand for the market.
Sedentary lifestyles, unhealthy eating habits, and an increasing burden of chronic illnesses (particularly cancer, diabetes, and cardiovascular disease) due to lack of exercise are critical drivers of market growth. Focusing on early detection and prevention of diseases is expected to promote the onset of diseases further.
For example, biomolecules can be analyzed to track brain health and activity, so that biomarkers can be applied in the treatment of various neurological disorders. The development of new ones, such as biomarker signatures, has improved the treatment rate of neurological diseases, leading to early diagnosis, non-invasive detection, and rapid drug development.
However, the low adoption of advanced biomarkers tests and the high cost of biomarkers developments & validation are restraining the growth of the biomarkers market in the Asia-Pacific region. The high capital expenditures, high costs of testing, and the need for low profit-to-cost ratios limit the APAC Biomarkers Market growth. The unfavorable policies by both private and public organizations are challenges in the APAC Biomarkers Market growth.
The Asia Pacific region is expected to grow at a significant compound annual growth rate of over 16.0% during the forecast period. Some factors contributing to growth include the presence of crucial biomarker participants in the region, strategic planning for joint product development, and increased R & D investment in developing countries. In emerging countries, the cost of clinical trials is relatively lower than in developed countries, which is expected to have a positive impact on expansion.
Noteworthy companies operating in the Asia Pacific Biomarkers Market profiled in this report are Bio-Rad Laboratories (U.S.), Qiagen N.V. (Netherlands), Enzo Biochem (U.S.), PerkinElmer, Inc. (U.S.), Merck & Co, Inc. (U.S.), EKF Diagnostics Holdings plc. (U.S.), Meso Scale Diagnostics, LLC (U.S.), Singulex, Inc. (U.S.), BioSims Technologies (France), Cisbio Bioassays (France) and Signosis, Inc. (U.S.)
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Product
5.1.1 Introduction
5.1.2 Consumables
5.1.3 Software
5.1.4 Services Growth Hormone Therapy
5.2 Type
5.2.1 Introduction
5.2.2 Safety Biomarkers
5.2.3 Efficacy Biomarkers
5.2.4 Validation Biomarkers
5.3 Application
5.3.1 Introduction
5.3.2 Diagnostics Development
5.3.3 Drug Discovery and Development
5.3.4 Personalised Medicine
5.3.5 Disease Risk Assessment
5.3.6 Other Applications
5.4 Disease Indications
5.4.1 Introduction
5.4.2 Cancer
5.4.3 CardiovascularDisorders
5.4.4 Neurological Disorders
5.4.5 Immunological Disorders
5.4.6 Other Diseases
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Bio-Rad Laboratories (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Qiagen N.V. (Netherlands)
8.3 Enzo Biochem (U.S.)
8.4 PerkinElmer, Inc. (U.S.)
8.5 Merck & Co, Inc. (U.S.)
8.6 EKF Diagnostics Holdings plc. (U.S.)
8.7 Meso Scale Diagnostics, LLC (U.S.)
8.8 Singulex, Inc. (U.S.)
8.9 BioSims Technologies (France)
8.10 Cisbio Bioassays (France)
8.11 Signosis, Inc. (U.S.)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
Apr 2021
